Amgen 4Q profit drops 16 pct. on higher spending

by Linda A. Johnson

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results fell short of Wall Street expectations.

The world's biggest biotech company, based in Thousand Oaks, California, said net income was $788 million, or $1.01 per share, for the three months ended Dec. 31. That was down from $934 million, or $1.08 per share, a year earlier.

Excluding one-time items, net income would have been $1.40 per share. That's 4 cents less than analysts expected, on average, according to research provider FactSet.

In after-hours trading, Amgen shares fell 21 cents to $82.86. They had fallen 22 cents in the regular session before the results were released.

The maker of anemia treatments and Epogen said revenue rose 11 percent to $4.42 billion. Analysts predicted sales of $4.37 billion.

Sales were led by treatment Enbrel, up 23 percent from the 2011 quarter to $1.16 billion, and Neulasta and Neupogen for fighting infection in cancer patients. They had a combined $1.31 billion in sales, down 1 percent.

Sales of Aranesp and fell 9 percent and 1 percent, respectively, to a combined $968 million.

Several newer drugs had double-digit jumps in revenue, including Prolia for osteoporosis, Xgeva for preventing fractures in cancerous bones and Sensipar for excessive and a thyroid disorder.

"We enter 2013 with good momentum, a broad late-stage pipeline and a continued focus on building our business internationally," Amgen CEO Robert A. Bradway said in a statement.

The company expects 2013 earnings per share of $6.85 to $7.15. That's above the average prediction of analysts for $7 per share.

Amgen predicted 2013 revenue will fall between $17.8 billion to $18.2 billion, compared with Wall Street's forecast for sales of $17.75 billion.

noted its free cash flow rose to $5.2 billion for 2012, from $4.5 billion in 2011.

For the full year, net income was $4.35 billion, or $5.52 per share. That was up from $3.68 billion, or $4.04 per share, in 2011. The 2012 per-share results got a significant boost from a sharp reduction in the number of outstanding shares.

Revenue rose 11 percent in 2012, to $17.27 billion from $15.58 billion.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Amgen posts higher 2Q sales, profit to beat views

Jul 27, 2012

(AP) — Amgen Inc.'s second-quarter net income rose 8 percent as the world's largest biotech company benefited from higher sales for its top-selling drugs and a gain from selling its share of an experimental medicine.

Qualcomm 3Q results beat Wall Street estimates

Jul 20, 2011

(AP) -- Wireless chip-maker Qualcomm Inc.'s results for the latest quarter beat Wall Street's expectations, and its projections for the current quarter are also above analysts' estimates.

CBS 4Q earnings top views, but sales fall short

Feb 16, 2012

(AP) -- Broadcasting giant CBS Corp. said Wednesday that its earnings rose 31 percent in the final quarter of 2011, thanks to licensing shows to online video companies such as Netflix as well as cost-cutting that helped ...

Recommended for you

Non-stop PET/CT scan provides accurate images

23 hours ago

Siemens is improving PET/CT imaging and data quality while reducing radiation exposure. The Biograph mCT Flow PET/CT scanner is a new positron emission tomography/computed tomography (PET/CT) system that, ...

Experts: Chopin's heart shows signs of TB

Sep 17, 2014

The preserved heart of composer Frederic Chopin contains signs of tuberculosis and possibly some other lung disease, medical experts said Wednesday.

The argument in favor of doping

Sep 17, 2014

Ahead of Friday's court ruling on whether ASADA's investigation into the Essendon Football Club was lawful, world leader in practical and medical ethics Professor Julian Savulescu, looks at whether there is a role for performance-enhancing ...

User comments